Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response
{{output}}
Introduction: Enfortumab vedotin (EV), alone or in combination with pembrolizumab (EV/P) are established treatment for metastatic urothelial carcinoma (mUC). Patients who discontinue EV after achieving a complete or partial respo... ...
